Who
Chris Degnan
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, UroGen Pharma; Chief Financial Officer, Galera Therapeutics; Chief Financial Officer, Verrica Pharmaceuticals.
In numbers
- Trades disclosed
- 18
- Buys
- 2
- Sells
- 2
- Bought
- $65K
- Sold
- $118K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 19 Jun 2018
- Last trade
- 8 Oct 2026
- Last filed
- 9 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Oct 2026filed 9 Oct 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —4,483 | filing |
| 8 Oct 2026filed 9 Oct 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $81K2,202 at $36.69 | filing |
| 8 Oct 2026filed 9 Oct 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,483 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,609 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,609 at $0.00 | filing |
| 8 Oct 2025filed 9 Oct 2025 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,483 at $0.00 | filing |
| 8 Oct 2025filed 9 Oct 2025 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —4,483 | filing |
| 8 Oct 2025filed 9 Oct 2025 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $37K2,203 at $16.85 | filing |
| 8 Oct 2024filed 9 Oct 2024 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,450 at $0.00 | filing |
| 8 Oct 2024filed 9 Oct 2024 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,142 at $0.00 | filing |
| 13 Mar 2023filed 14 Mar 2023 | Galera TherapeuticsBiotechnology | SEC FORM 4 Bought | $20K10,000 at $1.96 | filing |
| 25 Feb 2023filed 28 Feb 2023 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,000 at $0.00 | filing |
| 28 Feb 2022filed 2 Mar 2022 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 26 Jan 2021filed 28 Jan 2021 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —82,500 at $0.00 | filing |
| 31 Jan 2020filed 4 Feb 2020 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,435 at $0.00 | filing |
| 6 Nov 2019filed 8 Nov 2019 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —229,513 at $0.00 | filing |
| 28 Feb 2019filed 4 Mar 2019 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 19 Jun 2018filed 15 Aug 2018 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $45K3,000 at $15.00 | filing |
News
Urogen Pharma (NASDAQ:URGN) Stock: Insider Chris Degnan Sells 2,202 Sharesthemarketsdaily.com · 9 Oct 2026Analyzing Urogen Pharma (NASDAQ:URGN) and Incannex Healthcare (NASDAQ:IXHL)URGN · themarketsdaily.com · 15 Oct 2026Reviewing Cronos Group (NASDAQ:CRON) and Urogen Pharma (NASDAQ:URGN)URGN · tickerreport.com · 13 Oct 2026
1 headline in the last 90 days name Chris Degnan; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.